Dec 7 (Reuters) - Acorda Therapeutics Inc:
* ACORDA RESUBMITS NEW DRUG APPLICATION FOR INBRIJA™ (CVT-301, LEVODOPA INHALATION POWDER)
* SAYS RESUBMISSION ADDRESSED TWO ISSUES RAISED IN RECENT REFUSAL TO FILE (RTF) LETTER
* SAYS RESUBMISSION ALSO INCLUDED ALL ADDITIONAL INFORMATION REQUESTED BY FDA IN ITS LETTER
* SAYS INBRIJA NDA IS BEING SUBMITTED AS A 505(B)(2) APPLICATION Source text for Eikon: Further company coverage:
Our Standards: The Thomson Reuters Trust Principles.